Royal Bank of Canada Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD)

Royal Bank of Canada started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report sent to investors on Monday morning, MarketBeat reports. The firm issued an outperform rating and a $21.00 target price on the stock.

Separately, Cantor Fitzgerald began coverage on shares of Aardvark Therapeutics in a research note on Monday. They issued an “overweight” rating and a $50.00 price target on the stock.

Aardvark Therapeutics Trading Down 2.7 %

Shares of Aardvark Therapeutics stock opened at $10.14 on Monday. Aardvark Therapeutics has a 52 week low of $9.21 and a 52 week high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CFO Nelson Sun acquired 10,000 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now owns 99,484 shares of the company’s stock, valued at $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Tien-Li Lee acquired 16,542 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.